risankizumab vs SHR-1139

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-23 p19 · full Psoriasis pipeline

risankizumab · Skyrizi

Marketed by AbbVie and partners

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT02684370 · Phase 3 · completed

This randomized, triple-blind, placebo- and active-controlled trial used validated skin-clearance measures as its primary endpoints, and risankizumab achieved a highly statistically significant improvement over placebo on both: 75.3% vs 4.9% achieving PASI90, and 87.8% vs 7.8% achieving clear-or-almost-clear skin at Week 16.

Next expected readout: April 2028 · NCT04862286 (registry estimate)

Reported efficacy

Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16 (Baseline, Week 16); Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16; Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52: Co-primary endpoints at Week 16 (IMMhance study): PASI 90 73% risankizumab vs 2% placebo; sPGA 0/1 84% risankizumab vs 7% placebo; both p<0.001 (met)

Result source: NCT02672852

SHR-1139

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 2 in Psoriasismonoclonal antibody (dual IL-23p19/IL-36R)
Weak signal

NCT07051538 · Phase 1 · completed

This early-phase study randomized 64 participants to SHR-1139 or placebo under full blinding, but it was designed to check safety and tolerability, not to test whether the drug improves psoriasis, and no results have been posted, so no conclusion about benefit can yet be drawn from it. Its registered primary outcome on ClinicalTrials.gov is "Adverse events (AEs)" (with 3 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

Next expected readout: December 2026 · NCT07719530 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointrisankizumabSHR-1139
PASI 7585.2% vs 85.7%vs Ustekinumabwk 16 · n 54NCT04435600
19 other results
  • 83.3% vs 85.7% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 92.3% vs 85.7% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 86.7% vs 85.7% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 88.7% vs 8% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 90.8% vs 6.1% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 90.7% vs 71.7% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 86.8% vs 70% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 88.8% vs 69.7% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 93.3% vs 26.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 86.7% vs 20% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 75% vs 8.3% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 13.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 94.5% vs 8.6% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 89.7% vs 8.6% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 77.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 97.6% vs 77.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 67.4% vs 77.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 84.7% vs 18.8% wk 16 · n 118 · Phase 4 · secondary NCT04908475
  • 94% vs 77.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
—Not reported
PASI 9075.3% vs 4.9%+70.4 vs placebowk 16 · n 304NCT02684370
22 other results
  • 73.2% vs 2% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 74.8% vs 2% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 62.9% vs 3.8% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 72.4% vs 47.4% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 73.8% vs 65.6% wk 16 · n 164 · Phase 3 · primary NCT03478787
  • 75.3% vs 42% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 74.8% vs 47.5% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 64.8% vs 60.7% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 76.7% vs 11.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 61.7% vs 5% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 38.3% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 1.7% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 83.3% vs 60.7% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 84.6% vs 60.7% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 76.7% vs 60.7% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 74.5% vs 1.7% 150 mg · wk 16 · n 55 · Phase 2 · primary NCT03000075
  • 75.9% vs 1.7% 75 mg · wk 16 · n 58 · Phase 2 · primary NCT03000075
  • 81% vs 40% 180 mg · wk 12 · n 42 · Phase 2 · primary NCT02054481
  • 73.2% vs 40% 90 mg · wk 12 · n 41 · Phase 2 · primary NCT02054481
  • 32.6% vs 40% 18 mg · wk 12 · n 43 · Phase 2 · primary NCT02054481
  • 55.9% vs 5.1% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 77.1% vs 40% 90+180 mg · wk 12 · n 83 · Phase 2 · primary NCT02054481
—Not reported
PASI 10035.9% vs 0%+35.9 vs placebowk 16 · n 304NCT02684370
20 other results
  • 47.2% vs 1% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 50.7% vs 2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 38.1% vs 1.9% wk 16 · n 105 · Phase 3 · secondary NCT03875482
  • 35.9% vs 12% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 50.7% vs 24.2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 39.9% vs 23% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 40.7% vs 17.9% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 35% vs 1.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 23.3% vs 1.7% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 5% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 0% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 41.7% vs 17.9% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 53.8% vs 17.9% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 43.3% vs 17.9% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 32.7% vs 0% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 22.4% vs 0% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 50% vs 17.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 41.5% vs 17.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 14% vs 17.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 45.8% vs 17.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
—Not reported
sPGA 0/187.8% vs 7.8%+80 vs placebowk 16 · n 304NCT02684370
28 other results
  • 83.5% vs 7% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 83.7% vs 5.1% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 78.1% vs 9.6% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 83.7% vs 60.2% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 79.6% vs 75% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 68.5% vs 67.9% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 83.3% vs 75% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 75% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 90% vs 75% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 67.9% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 32.2% vs 11.5% wk 16 · n 87 · Phase 3 · secondary NCT04713592
  • 87.8% vs 63% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 83.7% vs 61.6% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 82.2% vs 65% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 82.3% vs 64.6% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 91.7% vs 31.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 90% vs 33.3% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 81.7% vs 15% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 33.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 75.4% vs 18.4% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 92.7% vs 10.3% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 86.2% vs 10.3% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 67.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 90.2% vs 67.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 62.8% vs 67.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 90.4% vs 67.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
—Not reported
DLQI, change-17 vs -9.7vs Fumadermwk 16 · n 59NCT03255382—Not reported

PASI 75

risankizumab
85.2% vs 85.7%vs Ustekinumabwk 16 · n 54NCT04435600
19 other results
  • 83.3% vs 85.7% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 92.3% vs 85.7% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 86.7% vs 85.7% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 88.7% vs 8% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 90.8% vs 6.1% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 90.7% vs 71.7% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 86.8% vs 70% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 88.8% vs 69.7% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 93.3% vs 26.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 86.7% vs 20% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 75% vs 8.3% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 13.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 94.5% vs 8.6% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 89.7% vs 8.6% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 77.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 97.6% vs 77.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 67.4% vs 77.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 84.7% vs 18.8% wk 16 · n 118 · Phase 4 · secondary NCT04908475
  • 94% vs 77.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
SHR-1139
—Not reported

PASI 90

risankizumab
75.3% vs 4.9%+70.4 vs placebowk 16 · n 304NCT02684370
22 other results
  • 73.2% vs 2% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 74.8% vs 2% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 62.9% vs 3.8% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 72.4% vs 47.4% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 73.8% vs 65.6% wk 16 · n 164 · Phase 3 · primary NCT03478787
  • 75.3% vs 42% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 74.8% vs 47.5% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 64.8% vs 60.7% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 76.7% vs 11.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 61.7% vs 5% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 38.3% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 1.7% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 83.3% vs 60.7% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 84.6% vs 60.7% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 76.7% vs 60.7% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 74.5% vs 1.7% 150 mg · wk 16 · n 55 · Phase 2 · primary NCT03000075
  • 75.9% vs 1.7% 75 mg · wk 16 · n 58 · Phase 2 · primary NCT03000075
  • 81% vs 40% 180 mg · wk 12 · n 42 · Phase 2 · primary NCT02054481
  • 73.2% vs 40% 90 mg · wk 12 · n 41 · Phase 2 · primary NCT02054481
  • 32.6% vs 40% 18 mg · wk 12 · n 43 · Phase 2 · primary NCT02054481
  • 55.9% vs 5.1% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 77.1% vs 40% 90+180 mg · wk 12 · n 83 · Phase 2 · primary NCT02054481
SHR-1139
—Not reported

PASI 100

risankizumab
35.9% vs 0%+35.9 vs placebowk 16 · n 304NCT02684370
20 other results
  • 47.2% vs 1% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 50.7% vs 2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 38.1% vs 1.9% wk 16 · n 105 · Phase 3 · secondary NCT03875482
  • 35.9% vs 12% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 50.7% vs 24.2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 39.9% vs 23% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 40.7% vs 17.9% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 35% vs 1.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 23.3% vs 1.7% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 5% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 0% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 41.7% vs 17.9% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 53.8% vs 17.9% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 43.3% vs 17.9% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 32.7% vs 0% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 22.4% vs 0% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 50% vs 17.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 41.5% vs 17.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 14% vs 17.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 45.8% vs 17.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
SHR-1139
—Not reported

sPGA 0/1

risankizumab
87.8% vs 7.8%+80 vs placebowk 16 · n 304NCT02684370
28 other results
  • 83.5% vs 7% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 83.7% vs 5.1% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 78.1% vs 9.6% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 83.7% vs 60.2% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 79.6% vs 75% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 68.5% vs 67.9% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 83.3% vs 75% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 75% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 90% vs 75% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 67.9% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 32.2% vs 11.5% wk 16 · n 87 · Phase 3 · secondary NCT04713592
  • 87.8% vs 63% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 83.7% vs 61.6% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 82.2% vs 65% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 82.3% vs 64.6% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 91.7% vs 31.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 90% vs 33.3% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 81.7% vs 15% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 33.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 75.4% vs 18.4% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 92.7% vs 10.3% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 86.2% vs 10.3% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 67.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 90.2% vs 67.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 62.8% vs 67.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 90.4% vs 67.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
SHR-1139
—Not reported

DLQI, change

risankizumab
-17 vs -9.7vs Fumadermwk 16 · n 59NCT03255382
SHR-1139
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SHR-1139: no structured comparison results are available for Psoriasis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. risankizumab: 4 of 4 rows · SHR-1139: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricrisankizumab
Dropout rate
1.6%Risankizumab (Part A)a
NCT02684370 · Phase 3
show 53 more results
—Risankizumab/Risankizumab (Part B)
NCT02684370 · Phase 3
1%Risankizumab (Part A1)
NCT02672852 · Phase 3
—Risankizumab/Risankizumab (Part B;
NCT02672852 · Phase 3
0%Part 1: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Non-r
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Respo
NCT04435600 · Phase 3
—Part 2 Period A: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period C: Risankizumab
NCT04435600 · Phase 3
—Part 3: Risankizumab
NCT04435600 · Phase 3
—Part 4: Risankizumab
NCT04435600 · Phase 3
0.7%Risankizumab (Part A)
NCT02684357 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02684357 · Phase 3
—Adalimumab/Rerandomized to Risanki
NCT02694523 · Phase 3
—Adalimumab/Risankizumab (Part B)
NCT02694523 · Phase 3
2.3%Risankizumab (Part A)
NCT02694523 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02694523 · Phase 3
1.8%Study-G Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-G Risankizumab/Risankizumab
NCT05969223 · Phase 4
0%Study-S Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-S Risankizumab/Risankizumab
NCT05969223 · Phase 4
—Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
26.2%150 mg
NCT03047395 · Phase 3 · registry result, not featured evidence
3.4%Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab (Double-blind Period)
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab (Open-la
NCT04713592 · Phase 3 · registry result, not featured evidence
16%
NCT04102007 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
11.1%
NCT03875508 · Phase 3 · registry result, not featured evidence
12.4%
NCT03875482 · Phase 3 · registry result, not featured evidence
7.9%
NCT03478787 · Phase 3 · registry result, not featured evidence
0%
NCT03255382 · Phase 3 · registry result, not featured evidence
70%600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
70%300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
—180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
4.8%180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
4.9%90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
9.3%18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.3%Risankizumab (Part A)a
NCT02684370 · Phase 3
show 53 more results
—Risankizumab/Risankizumab (Part B)
NCT02684370 · Phase 3
0.2%Risankizumab (Part A1)
NCT02672852 · Phase 3
—Risankizumab/Risankizumab (Part B;
NCT02672852 · Phase 3
—Part 1: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Non-r
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Respo
NCT04435600 · Phase 3
—Part 2 Period A: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period C: Risankizumab
NCT04435600 · Phase 3
—Part 3: Risankizumab
NCT04435600 · Phase 3
—Part 4: Risankizumab
NCT04435600 · Phase 3
0%Risankizumab (Part A)
NCT02684357 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02684357 · Phase 3
—Adalimumab/Rerandomized to Risanki
NCT02694523 · Phase 3
—Adalimumab/Risankizumab (Part B)
NCT02694523 · Phase 3
1%Risankizumab (Part A)
NCT02694523 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02694523 · Phase 3
—Study-G Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-G Risankizumab/Risankizumab
NCT05969223 · Phase 4
—Study-S Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-S Risankizumab/Risankizumab
NCT05969223 · Phase 4
—Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
6.5%150 mg
NCT03047395 · Phase 3 · registry result, not featured evidence
1.1%Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab (Double-blind Period)
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab (Open-la
NCT04713592 · Phase 3 · registry result, not featured evidence
1.6%
NCT04102007 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
0.9%
NCT03875508 · Phase 3 · registry result, not featured evidence
0%
NCT03875482 · Phase 3 · registry result, not featured evidence
0.6%
NCT03478787 · Phase 3 · registry result, not featured evidence
0%
NCT03255382 · Phase 3 · registry result, not featured evidence
—600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
—300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
—180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
2.4%90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
2.3%18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
Serious AEs
2.3%Risankizumab (Part A)a
NCT02684370 · Phase 3
show 53 more results
5.4%Risankizumab/Risankizumab (Part B)
NCT02684370 · Phase 3
2%Risankizumab (Part A1)
NCT02672852 · Phase 3
11.7%Risankizumab/Risankizumab (Part B;
NCT02672852 · Phase 3
0%Part 1: Risankizumab
NCT04435600 · Phase 3
10%Part 2 Period A Risankizumab Non-r
NCT04435600 · Phase 3
0%Part 2 Period A Risankizumab Respo
NCT04435600 · Phase 3
0%Part 2 Period A: Risankizumab
NCT04435600 · Phase 3
0%Part 2 Period C: Risankizumab
NCT04435600 · Phase 3
0%Part 3: Risankizumab
NCT04435600 · Phase 3
0%Part 4: Risankizumab
NCT04435600 · Phase 3
2%Risankizumab (Part A)
NCT02684357 · Phase 3
4.5%Risankizumab/Risankizumab (Part B)
NCT02684357 · Phase 3
5.7%Adalimumab/Rerandomized to Risanki
NCT02694523 · Phase 3
10.5%Adalimumab/Risankizumab (Part B)
NCT02694523 · Phase 3
3.3%Risankizumab (Part A)
NCT02694523 · Phase 3
4.1%Risankizumab/Risankizumab (Part B)
NCT02694523 · Phase 3
1.8%Study-G Risankizumab (Period A)
NCT05969223 · Phase 4
1.9%Study-G Risankizumab/Risankizumab
NCT05969223 · Phase 4
5.9%Study-S Risankizumab (Period A)
NCT05969223 · Phase 4
5.9%Study-S Risankizumab/Risankizumab
NCT05969223 · Phase 4
0.8%Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
0%Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
2.9%Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
6.9%Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
20%150 mg
NCT03047395 · Phase 3 · registry result, not featured evidence
—Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
5.7%Risankizumab (Double-blind Period)
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
6%Risankizumab/Risankizumab (Open-la
NCT04713592 · Phase 3 · registry result, not featured evidence
7%
NCT04102007 · Phase 3 · registry result, not featured evidence
25%150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
50%150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
20%75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
0%75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
5.6%
NCT03875508 · Phase 3 · registry result, not featured evidence
1%
NCT03875482 · Phase 3 · registry result, not featured evidence
5.5%
NCT03478787 · Phase 3 · registry result, not featured evidence
1.7%
NCT03255382 · Phase 3 · registry result, not featured evidence
0%600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
10%300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
8.7%180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
13.8%90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
3.6%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
1.9%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
7.4%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
3.4%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
1.8%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
14.6%90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
11.6%18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
a
viral upper respiratory tract infection 6.6% (placebo 5.9%)
upper respiratory tract infection 5.6% (placebo 2%)
headache 3% (placebo 2%)
NCT02684370 · Phase 3
show 48 more results
viral upper respiratory tract infection 13.5% (placebo 5.9%)
upper respiratory tract infection 10.1% (placebo 2%)
headache 1.7% (placebo 2%)
NCT02684370 · Phase 3
nasopharyngitis 5.2% (placebo 6%)
headache 3.4% (placebo 0%)
arthralgia 1.7% (placebo 2%)
NCT02672852 · Phase 3
nasopharyngitis 20.7% (placebo 6%)
upper respiratory tract infection 14.4% (placebo 5%)
arthralgia 9% (placebo 2%)
NCT02672852 · Phase 3
headache 16.7% (placebo 4.8%)
pyrexia 16.7% (placebo 0%)
abdominal pain 8.3% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 40% (placebo 9.5%)
covid-19 20% (placebo 9.5%)
conjunctivitis 10% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 22.7% (placebo 9.5%)
headache 18.2% (placebo 4.8%)
skin papilloma 13.6% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 18.5% (placebo 9.5%)
covid-19 9.3% (placebo 9.5%)
headache 5.6% (placebo 4.8%)
NCT04435600 · Phase 3
pyrexia 25% (placebo 0%)
bacterial vaginosis 12.5% (placebo 0%)
chills 12.5% (placebo 0%)
NCT04435600 · Phase 3
cough 15.4% (placebo 4.8%)
upper respiratory tract infection 15.4% (placebo 4.8%)
blood potassium increased 7.7% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 31.3% (placebo 9.5%)
pyrexia 12.5% (placebo 0%)
cough 9.4% (placebo 4.8%)
NCT04435600 · Phase 3
upper respiratory tract infection 3.7% (placebo 2%)
viral upper respiratory tract infection 3.4% (placebo 2%)
influenza 2% (placebo 1%)
NCT02684357 · Phase 3
viral upper respiratory tract infection 11.7% (placebo 2%)
upper respiratory tract infection 8.2% (placebo 2%)
diarrhoea 2.1% (placebo 3.1%)
NCT02684357 · Phase 3
viral upper respiratory tract infection 26.4%
upper respiratory tract infection 7.5%
headache 5.7%
NCT02694523 · Phase 3
viral upper respiratory tract infection 23.7%
hypertension 7.9%
upper respiratory tract infection 7.9%
NCT02694523 · Phase 3
viral upper respiratory tract infection 8.6%
upper respiratory tract infection 7%
headache 4%
NCT02694523 · Phase 3
viral upper respiratory tract infection 13.3%
upper respiratory tract infection 11.6%
hypertension 3.1%
NCT02694523 · Phase 3
upper respiratory tract infection 7.3% (placebo 3.7%)
covid-19 3.6% (placebo 3.7%)
nasopharyngitis 3.6% (placebo 3.7%)
NCT05969223 · Phase 4
upper respiratory tract infection 7.4% (placebo 3.7%)
covid-19 3.7% (placebo 3.7%)
nasopharyngitis 3.7% (placebo 3.7%)
NCT05969223 · Phase 4
upper respiratory tract infection 11.8% (placebo 3.7%)
covid-19 7.8% (placebo 3.7%)
nasopharyngitis 2% (placebo 3.7%)
NCT05969223 · Phase 4
upper respiratory tract infection 11.8% (placebo 3.7%)
covid-19 7.8% (placebo 3.7%)
nasopharyngitis 2% (placebo 3.7%)
NCT05969223 · Phase 4
covid-19 11%
nasopharyngitis 3.4%
headache 2.5%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 12.5%
nasopharyngitis 10.4%
hypertension 6.3%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 11.8%
nasopharyngitis 9.8%
upper respiratory tract infection 5.9%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 16.4%
nasopharyngitis 9.5%
hypertension 5.2%
NCT04908475 · Phase 4 · registry result, not featured evidence
150 mg
nasopharyngitis 22.1%
covid-19 16.6%
upper respiratory tract infection 14.4%
NCT03047395 · Phase 3 · registry result, not featured evidence
covid-19 2.3% (placebo 2.3%)
NCT04713592 · Phase 3 · registry result, not featured evidence
covid-19 14.3% (placebo 2.3%)
NCT04713592 · Phase 3 · registry result, not featured evidence
covid-19 8.6%
nasopharyngitis 5.7%
NCT04102007 · Phase 3 · registry result, not featured evidence
150 mg
viral upper respiratory tract infection 75%
otitis media 50%
acne 25%
NCT03022045 · Phase 3 · registry result, not featured evidence
150 mg
dehydration 50%
abdominal pain upper 25%
acne 25%
NCT03022045 · Phase 3 · registry result, not featured evidence
75 mg
viral upper respiratory tract infection 60%
constipation 20%
diarrhoea 20%
NCT03022045 · Phase 3 · registry result, not featured evidence
75 mg
alanine aminotransferase increased 25%
aspartate aminotransferase increased 25%
erythema 25%
NCT03022045 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.4%
upper respiratory tract infection 5.6%
NCT03875508 · Phase 3 · registry result, not featured evidence
nasopharyngitis 21.3%
upper respiratory tract infection 12.8%
arthralgia 5.5%
NCT03478787 · Phase 3 · registry result, not featured evidence
nasopharyngitis 58.3%
headache 8.3%
oropharyngeal pain 8.3%
NCT03255382 · Phase 3 · registry result, not featured evidence
600 mg
upper respiratory infection 50%
common cold 30%
covid-19 infection 30%
NCT05283135 · Phase 2 · registry result, not featured evidence
300 mg
upper respiratory infection 20%
bleeding internal hemorrhoids 10%
bursitis, left elbow 10%
NCT05283135 · Phase 2 · registry result, not featured evidence
180 mg
upper respiratory tract infection 17.4%
dermatitis contact 13%
nasopharyngitis 13%
NCT02203851 · Phase 2 · registry result, not featured evidence
90 mg
nasopharyngitis 18.4%
upper respiratory tract infection 12.6%
arthralgia 10.3%
NCT02203851 · Phase 2 · registry result, not featured evidence
150 mg
nasopharyngitis 29.6% (placebo 13.8%)
arthralgia 11.1% (placebo 1.7%)
oral herpes 7.4% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
150 mg
nasopharyngitis 18.2% (placebo 13.8%)
arthralgia 3.6% (placebo 1.7%)
back pain 1.8% (placebo 1.7%)
NCT03000075 · Phase 2 · registry result, not featured evidence
150 mg
nasopharyngitis 20.4% (placebo 13.8%)
dental caries 7.4% (placebo 1.7%)
blood triglycerides increased 5.6% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
75 mg
nasopharyngitis 29.6% (placebo 13.8%)
arthralgia 11.1% (placebo 1.7%)
asteatosis 7.4% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
75 mg
diabetes mellitus 5.2% (placebo 1.7%)
nasopharyngitis 5.2% (placebo 13.8%)
back pain 3.4% (placebo 1.7%)
NCT03000075 · Phase 2 · registry result, not featured evidence
75 mg
nasopharyngitis 21.4% (placebo 13.8%)
hepatic function abnormal 5.4% (placebo 0%)
influenza 5.4% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
180 mg
nasopharyngitis 26.2%
arthralgia 7.1%
headache 7.1%
NCT02054481 · Phase 2 · registry result, not featured evidence
90 mg
nasopharyngitis 34.1%
back pain 9.8%
gastroenteritis 9.8%
NCT02054481 · Phase 2 · registry result, not featured evidence
18 mg
nasopharyngitis 34.9%
headache 11.6%
folliculitis 7%
NCT02054481 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

risankizumab

PASI 90 74.5% (n=55) vs 1.7% (n=58) placebo @ 16wk150 mg
responder rate · % of participants
NCT03000075 · Phase 2 · registry result, not featured evidence
show 34 more results
75.9% (n=58) vs 1.7% (n=58) placebo @ 16wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
81% (n=42) vs 40% (n=40) Stelara @ 12wk180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
85.7% (n=42) vs 55% (n=40) Stelara @ 24wk180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
73.2% (n=41) vs 40% (n=40) Stelara @ 12wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
65.9% (n=41) vs 55% (n=40) Stelara @ 24wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
32.6% (n=43) vs 40% (n=40) Stelara @ 12wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
30.2% (n=43) vs 55% (n=40) Stelara @ 24wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
75.3% (n=304) vs 4.9% (n=102) placebo @ 16wk
NCT02684370 · Phase 3
75.3% (n=304) vs 42% (n=100) Ustekinumab @ 16wk
NCT02684370 · Phase 3
81.9% (n=304) vs 44% (n=100) Ustekinumab @ 52wk
NCT02684370 · Phase 3
73.2% (n=407) vs 2% (n=100) placebo @ 16wk
NCT02672852 · Phase 3
85.6% (n=111) vs 52.4% (n=225) placebo @ 52wk
NCT02672852 · Phase 3
83.3% (n=12) vs 60.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
64.8% (n=54) vs 60.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
84.6% (n=13) vs 60.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
76.7% (n=30) vs 60.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
74.8% (n=294) vs 2% (n=98) placebo @ 16wk
NCT02684357 · Phase 3
74.8% (n=294) vs 47.5% (n=99) Ustekinumab @ 16wk
NCT02684357 · Phase 3
80.6% (n=294) vs 50.5% (n=99) Ustekinumab @ 52wk
NCT02684357 · Phase 3
72.4% (n=301) vs 47.4% (n=304) Adalimumab @ 16wk
NCT02694523 · Phase 3
66% (n=53) vs 21.4% (n=56) Adalimumab @ 44wk
NCT02694523 · Phase 3
55.9% (n=118) vs 5.1% (n=234) APR @ 16wk
NCT04908475 · Phase 4 · registry result, not featured evidence
72.3% (n=83) vs 2.6% (n=78) APR @ 52wk
NCT04908475 · Phase 4 · registry result, not featured evidence
62.9% (n=105) vs 3.8% (n=52) placebo @ 16wk
NCT03875482 · Phase 3 · registry result, not featured evidence
73.8% (n=164) vs 65.6% (n=163) Secukinumab @ 16wk
NCT03478787 · Phase 3 · registry result, not featured evidence
86.6% (n=164) vs 57.1% (n=163) Secukinumab @ 52wk
NCT03478787 · Phase 3 · registry result, not featured evidence
83.3% (n=60) vs 10% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
1.7% (n=60) vs 0% (n=60) Fumaderm @ 4wk
NCT03255382 · Phase 3 · registry result, not featured evidence
38.3% (n=60) vs 1.7% (n=60) Fumaderm @ 8wk
NCT03255382 · Phase 3 · registry result, not featured evidence
61.7% (n=60) vs 5% (n=60) Fumaderm @ 12wk
NCT03255382 · Phase 3 · registry result, not featured evidence
76.7% (n=60) vs 11.7% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
83.3% (n=60) vs 16.7% (n=60) Fumaderm @ 20wk
NCT03255382 · Phase 3 · registry result, not featured evidence
77.1% (n=83) vs 40% (n=40) Stelara @ 12wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
75.9% (n=83) vs 55% (n=40) Stelara @ 24wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
sPGA 0/1 92.7% (n=55) vs 10.3% (n=58) placebo @ 16wk150 mg
responder rate · % of participants
NCT03000075 · Phase 2 · registry result, not featured evidence
show 36 more results
86.2% (n=58) vs 10.3% (n=58) placebo @ 16wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
90.5% (n=42) vs 67.5% (n=40) Stelara @ 12wk180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
90.2% (n=41) vs 67.5% (n=40) Stelara @ 12wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
62.8% (n=43) vs 67.5% (n=40) Stelara @ 12wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
87.8% (n=304) vs 7.8% (n=102) placebo @ 16wk
NCT02684370 · Phase 3
87.8% (n=304) vs 63% (n=100) Ustekinumab @ 16wk
NCT02684370 · Phase 3
82.2% (n=304) vs 65% (n=100) Ustekinumab @ 12wk
NCT02684370 · Phase 3
83.5% (n=407) vs 7% (n=100) placebo @ 16wk
NCT02672852 · Phase 3
87.4% (n=111) vs 61.3% (n=225) placebo @ 52wk
NCT02672852 · Phase 3
81.1% (n=111) vs 7.1% (n=225) placebo @ 104wk
NCT02672852 · Phase 3
83.3% (n=12) vs 75% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
79.6% (n=54) vs 75% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
84.6% (n=13) vs 75% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
90% (n=30) vs 75% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
83.3% (n=12) vs 67.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
68.5% (n=54) vs 67.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
84.6% (n=13) vs 67.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
83.3% (n=30) vs 67.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
83.7% (n=294) vs 5.1% (n=98) placebo @ 16wk
NCT02684357 · Phase 3
83.7% (n=294) vs 61.6% (n=99) Ustekinumab @ 16wk
NCT02684357 · Phase 3
82.3% (n=294) vs 64.6% (n=99) Ustekinumab @ 12wk
NCT02684357 · Phase 3
83.3% (n=294) vs 54.5% (n=99) Ustekinumab @ 52wk
NCT02684357 · Phase 3
83.7% (n=301) vs 60.2% (n=304) Adalimumab @ 16wk
NCT02694523 · Phase 3
73.6% (n=53) vs 33.9% (n=56) Adalimumab @ 44wk
NCT02694523 · Phase 3
75.4% (n=118) vs 18.4% (n=234) APR @ 16wk
NCT04908475 · Phase 4 · registry result, not featured evidence
77.1% (n=83) vs 7.7% (n=78) APR @ 52wk
NCT04908475 · Phase 4 · registry result, not featured evidence
32.2% (n=87) vs 11.5% (n=87) placebo @ 16wk
NCT04713592 · Phase 3 · registry result, not featured evidence
78.1% (n=105) vs 9.6% (n=52) placebo @ 16wk
NCT03875482 · Phase 3 · registry result, not featured evidence
87.8% (n=164) vs 58.3% (n=163) Secukinumab @ 52wk
NCT03478787 · Phase 3 · registry result, not featured evidence
33.3% (n=60) vs 3.3% (n=60) Fumaderm @ 4wk
NCT03255382 · Phase 3 · registry result, not featured evidence
81.7% (n=60) vs 15% (n=60) Fumaderm @ 8wk
NCT03255382 · Phase 3 · registry result, not featured evidence
90% (n=60) vs 33.3% (n=60) Fumaderm @ 12wk
NCT03255382 · Phase 3 · registry result, not featured evidence
91.7% (n=60) vs 31.7% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
93.3% (n=60) vs 48.3% (n=60) Fumaderm @ 20wk
NCT03255382 · Phase 3 · registry result, not featured evidence
93.3% (n=60) vs 38.3% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
90.4% (n=83) vs 67.5% (n=40) Stelara @ 12wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
sPGA (0 36.8% (n=304) vs 2% (n=102) placebo @ 16wk
responder rate · % of participants
NCT02684370 · Phase 3
show 15 more results
36.8% (n=304) vs 14% (n=100) Ustekinumab @ 16wk
NCT02684370 · Phase 3
57.6% (n=304) vs 21% (n=100) Ustekinumab @ 52wk
NCT02684370 · Phase 3
46.4% (n=407) vs 1% (n=100) placebo @ 16wk
NCT02672852 · Phase 3
51% (n=294) vs 3.1% (n=98) placebo @ 16wk
NCT02684357 · Phase 3
51% (n=294) vs 25.3% (n=99) Ustekinumab @ 16wk
NCT02684357 · Phase 3
59.5% (n=294) vs 30.3% (n=99) Ustekinumab @ 52wk
NCT02684357 · Phase 3
39.6% (n=53) vs 7.1% (n=56) Adalimumab @ 44wk
NCT02694523 · Phase 3
50.9% (n=55) vs 5.6% (n=54) placebo @ 16wk
NCT05969223 · Phase 4
39% (n=105) vs 1.9% (n=52) placebo @ 16wk
NCT03875482 · Phase 3 · registry result, not featured evidence
1.7% (n=60) vs 0% (n=60) Fumaderm @ 4wk
NCT03255382 · Phase 3 · registry result, not featured evidence
10% (n=60) vs 1.7% (n=60) Fumaderm @ 8wk
NCT03255382 · Phase 3 · registry result, not featured evidence
21.7% (n=60) vs 3.3% (n=60) Fumaderm @ 12wk
NCT03255382 · Phase 3 · registry result, not featured evidence
36.7% (n=60) vs 3.3% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
48.3% (n=60) vs 6.7% (n=60) Fumaderm @ 20wk
NCT03255382 · Phase 3 · registry result, not featured evidence
51.7% (n=60) vs 5% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
PASI 100 32.7% (n=55) vs 0% (n=58) placebo @ 16wk150 mg
responder rate · % of participants
NCT03000075 · Phase 2 · registry result, not featured evidence
show 27 more results
22.4% (n=58) vs 0% (n=58) placebo @ 16wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
50% (n=42) vs 17.5% (n=40) Stelara @ 12wk180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
41.5% (n=41) vs 17.5% (n=40) Stelara @ 12wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
14% (n=43) vs 17.5% (n=40) Stelara @ 12wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
35.9% (n=304) vs 0% (n=102) placebo @ 16wk
NCT02684370 · Phase 3
35.9% (n=304) vs 12% (n=100) Ustekinumab @ 16wk
NCT02684370 · Phase 3
56.3% (n=100) vs 21% (n=304) Ustekinumab @ 52wk
NCT02684370 · Phase 3
47.2% (n=407) vs 1% (n=100) placebo @ 16wk
NCT02672852 · Phase 3
64% (n=111) vs 30.2% (n=225) placebo @ 52wk
NCT02672852 · Phase 3
41.7% (n=12) vs 17.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
40.7% (n=54) vs 17.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
53.8% (n=13) vs 17.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
43.3% (n=30) vs 17.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
50.7% (n=294) vs 2% (n=98) placebo @ 16wk
NCT02684357 · Phase 3
50.7% (n=294) vs 24.2% (n=99) Ustekinumab @ 16wk
NCT02684357 · Phase 3
59.5% (n=294) vs 30.3% (n=99) Ustekinumab @ 52wk
NCT02684357 · Phase 3
39.9% (n=301) vs 23% (n=304) Adalimumab @ 16wk
NCT02694523 · Phase 3
39.6% (n=53) vs 7.1% (n=56) Adalimumab @ 44wk
NCT02694523 · Phase 3
38.1% (n=105) vs 1.9% (n=52) placebo @ 16wk
NCT03875482 · Phase 3 · registry result, not featured evidence
65.9% (n=164) vs 39.9% (n=163) Secukinumab @ 52wk
NCT03478787 · Phase 3 · registry result, not featured evidence
0% (n=60) vs 0% (n=60) Fumaderm @ 4wk
NCT03255382 · Phase 3 · registry result, not featured evidence
5% (n=60) vs 1.7% (n=60) Fumaderm @ 8wk
NCT03255382 · Phase 3 · registry result, not featured evidence
23.3% (n=60) vs 1.7% (n=60) Fumaderm @ 12wk
NCT03255382 · Phase 3 · registry result, not featured evidence
35% (n=60) vs 1.7% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
48.3% (n=60) vs 6.7% (n=60) Fumaderm @ 20wk
NCT03255382 · Phase 3 · registry result, not featured evidence
50% (n=60) vs 5% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
45.8% (n=83) vs 17.5% (n=40) Stelara @ 12wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
DLQI 0/1 65.8% (n=304) vs 7.8% (n=102) placebo @ 16wk
responder rate · % of participants
NCT02684370 · Phase 3
show 7 more results
65.8% (n=304) vs 43% (n=100) Ustekinumab @ 16wk
NCT02684370 · Phase 3
65.4% (n=407) vs 3% (n=100) placebo @ 16wk
NCT02672852 · Phase 3
66.7% (n=294) vs 4.1% (n=98) placebo @ 16wk
NCT02684357 · Phase 3
66.7% (n=294) vs 46.5% (n=99) Ustekinumab @ 16wk
NCT02684357 · Phase 3
60% (n=55) vs 3.7% (n=54) placebo @ 16wk
NCT05969223 · Phase 4
48.3% (n=60) vs 10% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
66.7% (n=60) vs 10% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
PASI 75 94.5% (n=55) vs 8.6% (n=58) placebo @ 16wk150 mg
responder rate · % of participants
NCT03000075 · Phase 2 · registry result, not featured evidence
show 29 more results
89.7% (n=58) vs 8.6% (n=58) placebo @ 16wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
90.5% (n=42) vs 77.5% (n=40) Stelara @ 12wk180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
92.9% (n=42) vs 70% (n=40) Stelara @ 24wk180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
97.6% (n=41) vs 77.5% (n=40) Stelara @ 12wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
92.7% (n=41) vs 70% (n=40) Stelara @ 24wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
67.4% (n=43) vs 77.5% (n=40) Stelara @ 12wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
55.8% (n=43) vs 70% (n=40) Stelara @ 24wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
86.8% (n=304) vs 70% (n=100) Ustekinumab @ 12wk
NCT02684370 · Phase 3
88.7% (n=407) vs 8% (n=100) placebo @ 16wk
NCT02672852 · Phase 3
92.8% (n=111) vs 71.6% (n=225) placebo @ 52wk
NCT02672852 · Phase 3
83.3% (n=12) vs 85.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
85.2% (n=54) vs 85.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
92.3% (n=13) vs 85.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
86.7% (n=30) vs 85.7% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
88.8% (n=294) vs 69.7% (n=99) Ustekinumab @ 12wk
NCT02684357 · Phase 3
90.8% (n=294) vs 6.1% (n=98) placebo @ 16wk
NCT02684357 · Phase 3
91.5% (n=294) vs 76.8% (n=99) Ustekinumab @ 52wk
NCT02684357 · Phase 3
90.7% (n=301) vs 71.7% (n=304) Adalimumab @ 16wk
NCT02694523 · Phase 3
84.7% (n=118) vs 18.8% (n=234) APR @ 16wk
NCT04908475 · Phase 4 · registry result, not featured evidence
83.1% (n=83) vs 11.5% (n=78) APR @ 52wk
NCT04908475 · Phase 4 · registry result, not featured evidence
89.6% (n=164) vs 69.9% (n=163) Secukinumab @ 52wk
NCT03478787 · Phase 3 · registry result, not featured evidence
13.3% (n=60) vs 3.3% (n=60) Fumaderm @ 4wk
NCT03255382 · Phase 3 · registry result, not featured evidence
75% (n=60) vs 8.3% (n=60) Fumaderm @ 8wk
NCT03255382 · Phase 3 · registry result, not featured evidence
86.7% (n=60) vs 20% (n=60) Fumaderm @ 12wk
NCT03255382 · Phase 3 · registry result, not featured evidence
93.3% (n=60) vs 26.7% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
95% (n=60) vs 38.3% (n=60) Fumaderm @ 20wk
NCT03255382 · Phase 3 · registry result, not featured evidence
98.3% (n=60) vs 33.3% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
94% (n=83) vs 77.5% (n=40) Stelara @ 12wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
92.8% (n=83) vs 70% (n=40) Stelara @ 24wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
PSS Total -5.608 vs 0.157 placebo score @ 16wk
absolute change · score
NCT02684370 · Phase 3
show 3 more results
-6.013 vs -1.036 placebo score @ 16wk
NCT05969223 · Phase 4
-8.7 vs -5.5 Fumaderm score @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
-9.5 vs -5.6 Fumaderm score @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
sPGA 0/1 88.9% (n=27) @ 52wk150 mg
responder rate · % of participants
No placebo or comparator arm
NCT03000075 · Phase 2 · registry result, not featured evidence
show 12 more results
94.5% (n=55) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
96.3% (n=27) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
84.5% (n=58) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
68.8% (n=32) @ 48wk180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
70.4% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
63.6% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
62.5% (n=8) @ 16wk
NCT04435600 · Phase 3
62.5% (n=8) @ 16wk
NCT04435600 · Phase 3
57.4% (n=244) @ 16wk*
NCT04102007 · Phase 3 · registry result, not featured evidence · converted to % from 140 Participants as posted
62.3% (n=244) @ 52wk*
NCT04102007 · Phase 3 · registry result, not featured evidence · converted to % from 152 Participants as posted
81.5% (n=108) @ 16wk
NCT03875508 · Phase 3 · registry result, not featured evidence
66.7% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence
PASI 50 95.2% (n=42) vs 87.5% (n=40) Stelara @ 12wk180 mg
responder rate · % of participants
NCT02054481 · Phase 2 · registry result, not featured evidence
show 13 more results
100% (n=41) vs 87.5% (n=40) Stelara @ 12wk90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
93% (n=43) vs 87.5% (n=40) Stelara @ 12wk18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
91.7% (n=12) vs 92.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
90.7% (n=54) vs 92.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
100% (n=13) vs 92.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
96.7% (n=30) vs 92.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
53.3% (n=60) vs 6.7% (n=60) Fumaderm @ 4wk
NCT03255382 · Phase 3 · registry result, not featured evidence
91.7% (n=60) vs 28.3% (n=60) Fumaderm @ 8wk
NCT03255382 · Phase 3 · registry result, not featured evidence
100% (n=60) vs 46.7% (n=60) Fumaderm @ 12wk
NCT03255382 · Phase 3 · registry result, not featured evidence
100% (n=60) vs 60% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
100% (n=60) vs 63.3% (n=60) Fumaderm @ 20wk
NCT03255382 · Phase 3 · registry result, not featured evidence
100% (n=60) vs 53.3% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
97.6% (n=83) vs 87.5% (n=40) Stelara @ 12wk90+180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
PASI 50 100% (n=32) @ 48wk180 mg
responder rate · % of participants
No placebo or comparator arm
NCT02203851 · Phase 2 · registry result, not featured evidence
show 4 more results
96.3% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
95.5% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
87.5% (n=8) @ 16wk
NCT04435600 · Phase 3
100% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence
PASI 90 75% (n=4) @ 16wk150 mg
responder rate · % of participants
No placebo or comparator arm
NCT03022045 · Phase 3 · registry result, not featured evidence
show 13 more results
100% (n=4) @ 16wk150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
85.2% (n=27) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
92.7% (n=55) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
100% (n=4) @ 16wk75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
60% (n=5) @ 16wk75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
81.5% (n=27) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
86.2% (n=58) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
71.9% (n=32) @ 48wk180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
77.8% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
72.7% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
87.5% (n=8) @ 16wk
NCT04435600 · Phase 3
66.7% (n=108) @ 16wk
NCT03875508 · Phase 3 · registry result, not featured evidence
74.1% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence
PASI 100 44.4% (n=27) @ 52wk150 mg
responder rate · % of participants
No placebo or comparator arm
NCT03000075 · Phase 2 · registry result, not featured evidence
show 15 more results
41.8% (n=55) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
40.7% (n=27) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
43.1% (n=58) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
77.8% (n=9) @ 28wk*600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
66.7% (n=9) @ 40wk*600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
44.4% (n=9) @ 52wk*600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted
88.9% (n=9) @ 28wk*300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
66.7% (n=9) @ 40wk*300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
44.4% (n=9) @ 52wk*300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted
50% (n=32) @ 48wk180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
55.6% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
54.5% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
25% (n=8) @ 16wk
NCT04435600 · Phase 3
46.3% (n=108) @ 16wk
NCT03875508 · Phase 3 · registry result, not featured evidence
55.6% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence

+ 47 further endpoints in the CSV export.

Ulcerative Colitis

Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline

risankizumab · Skyrizi

Marketed by AbbVie and partners

Approved in Ulcerative Colitismonoclonal antibody
Reliable signal

NCT03398148 · Phase 2/3 · completed

Design meets the 'strong' test: randomized, double-blind (participant and investigator masked), placebo-controlled, large adequately powered sample (n=1555 treated), hard clinical/endoscopic composite endpoint (Adapted Mayo Score remission including endoscopic subscore), and the primary comparison was statistically significant in the favorable direction for all randomized dose arms in both substudies.

Next expected readout: August 2027 · NCT06880744 (registry estimate)

Reported efficacy

clinical remission + endoscopic improvement met (met)

Result source: INSPIRE/COMMAND

SHR-1139

Developed by Jiangsu Hengrui Pharmaceuticals

Phase 2 in Ulcerative Colitismonoclonal antibody (dual IL-23p19/IL-36R)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2027 · NCT07232576 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointrisankizumabSHR-1139
Clinical remission (induction)20.3% vs 6.2%+14.1 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
4 other results
  • 12.4% vs 1.7% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · primary NCT03398148
  • 9.8% vs 1.7% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
  • 10.3% vs 1.7% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · primary NCT03398148
  • 11.5% vs 1.7% 600 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
—Not reported
Clinical remission (maintenance)—Trial running · NCT03398135—Not reported
Clinical response (induction)64.3% vs 35.7%+28.6 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
9 other results
  • 52.2% vs 30.5% 1200 mg IV · wk 4 · n 650 · Phase 2/3 · secondary NCT03398148
  • 46.2% vs 20% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · secondary NCT03398148
  • 43.5% vs 25% 1800 mg IV · wk 4 · n 340 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 20% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 25% 1200 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
  • 53.4% vs 20% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · secondary NCT03398148
  • 37.9% vs 25% 1800 mg IV · wk 4 · n 58 · Phase 2/3 · secondary NCT03398148
  • 42.6% vs 20% 600 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 32.8% vs 25% 600 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
—Not reported
Endoscopic improvement (induction)36.5% vs 12.1%+24.4 vs placebo1200 mg IV · wk 12 · n 650NCT03398148—Not reported
Corticosteroid-free remission (maintenance)—Trial running · NCT03398135—Not reported

Clinical remission (induction)

risankizumab
20.3% vs 6.2%+14.1 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
4 other results
  • 12.4% vs 1.7% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · primary NCT03398148
  • 9.8% vs 1.7% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
  • 10.3% vs 1.7% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · primary NCT03398148
  • 11.5% vs 1.7% 600 mg IV · wk 12 · n 61 · Phase 2/3 · primary NCT03398148
SHR-1139
—Not reported

Clinical remission (maintenance)

risankizumab
—Trial running · NCT03398135
SHR-1139
—Not reported

Clinical response (induction)

risankizumab
64.3% vs 35.7%+28.6 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
9 other results
  • 52.2% vs 30.5% 1200 mg IV · wk 4 · n 650 · Phase 2/3 · secondary NCT03398148
  • 46.2% vs 20% 1800 mg IV · wk 12 · n 340 · Phase 2/3 · secondary NCT03398148
  • 43.5% vs 25% 1800 mg IV · wk 4 · n 340 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 20% 1200 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 45.9% vs 25% 1200 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
  • 53.4% vs 20% 1800 mg IV · wk 12 · n 58 · Phase 2/3 · secondary NCT03398148
  • 37.9% vs 25% 1800 mg IV · wk 4 · n 58 · Phase 2/3 · secondary NCT03398148
  • 42.6% vs 20% 600 mg IV · wk 12 · n 61 · Phase 2/3 · secondary NCT03398148
  • 32.8% vs 25% 600 mg IV · wk 4 · n 61 · Phase 2/3 · secondary NCT03398148
SHR-1139
—Not reported

Endoscopic improvement (induction)

risankizumab
36.5% vs 12.1%+24.4 vs placebo1200 mg IV · wk 12 · n 650NCT03398148
SHR-1139
—Not reported

Corticosteroid-free remission (maintenance)

risankizumab
—Trial running · NCT03398135
SHR-1139
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

SHR-1139: no structured comparison results are available for Ulcerative Colitis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. risankizumab: 4 of 4 rows · SHR-1139: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricrisankizumab
Dropout rate
4.9%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.7%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
10.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.8%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Discontinued due to AEs
3.3%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
0%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
3.3%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Serious AEs
6.6%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 13 more results
2.6%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.5%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.3%1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.9%360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1.4%360 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.5%180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
5.6%180 mg SC
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.6%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
—1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
2.7%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.3%1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
9.7%600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
Most frequent reported AEs
1200 mg IV
colitis ulcerative 4.9% (placebo 8.5%)
headache 4.9% (placebo 5.1%)
nasopharyngitis 4.9% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 12 more results
1200 mg IV
covid-19 4.6% (placebo 0%)
anaemia 3.2% (placebo 3.4%)
headache 2.9% (placebo 5.1%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1200 mg IV
covid-19 5.9% (placebo 0%)
headache 2.9% (placebo 5.1%)
anaemia 1.5% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1200 mg IV
covid-19 5.7% (placebo 0%)
anaemia 2.9% (placebo 3.4%)
colitis ulcerative 1.7% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
360 mg SC
nasopharyngitis 8.5% (placebo 6.8%)
headache 7% (placebo 5.1%)
colitis ulcerative 4.2% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
360 mg SC
anaemia 8.5% (placebo 3.4%)
covid-19 8.5% (placebo 0%)
headache 8.5% (placebo 5.1%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
180 mg SC
headache 2.8% (placebo 5.1%)
anaemia 1.4% (placebo 3.4%)
nasopharyngitis 1.4% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
180 mg SC
covid-19 5.6% (placebo 0%)
colitis ulcerative 4.2% (placebo 8.5%)
anaemia 2.8% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 8.6% (placebo 6.8%)
headache 6.9% (placebo 5.1%)
anaemia 1.7% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 7% (placebo 6.8%)
headache 6.5% (placebo 5.1%)
anaemia 3.5% (placebo 3.4%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
nasopharyngitis 10.8% (placebo 6.8%)
anaemia 2.7% (placebo 3.4%)
colitis ulcerative 2.7% (placebo 8.5%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
1800 mg IV
dry skin 5.6% (placebo 0%)
headache 5.6% (placebo 5.1%)
nasopharyngitis 5.6% (placebo 6.8%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
600 mg IV
nasopharyngitis 8.1% (placebo 6.8%)
bronchitis 6.5% (placebo 0%)
dry skin 3.2% (placebo 0%)
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

risankizumab

Clinical Remission 9.8% (n=61) vs 1.7% (n=60) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 6 Participants as posted
show 4 more results
20.3% (n=650) vs 6.2% (n=325) placebo @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
10.3% (n=58) vs 1.7% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 6 Participants as posted
12.4% (n=340) vs 1.7% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 42 Participants as posted
11.5% (n=61) vs 1.7% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 7 Participants as posted
Endoscopic Improvement 13.1% (n=61) vs 5% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 8 Participants as posted
show 3 more results
15.5% (n=58) vs 5% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 9 Participants as posted
17.9% (n=340) vs 5% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 61 Participants as posted
24.6% (n=61) vs 5% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 15 Participants as posted
Clinical Response 45.9% (n=61) vs 20% (n=60) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 28 Participants as posted
show 9 more results
45.9% (n=61) vs 25% (n=60) placebo @ 4wk*1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 28 Participants as posted
64.3% (n=650) vs 35.7% (n=325) placebo @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
52.2% (n=650) vs 30.5% (n=325) placebo @ 4wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
53.4% (n=58) vs 20% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 31 Participants as posted
46.2% (n=340) vs 20% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 157 Participants as posted
37.9% (n=58) vs 25% (n=60) placebo @ 4wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 22 Participants as posted
43.5% (n=340) vs 25% (n=60) placebo @ 4wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 148 Participants as posted
42.6% (n=61) vs 20% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 26 Participants as posted
32.8% (n=61) vs 25% (n=60) placebo @ 4wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 20 Participants as posted
Endoscopic Remission 4.9% (n=61) vs 0% (n=60) placebo @ 12wk1200 mg IV
responder rate · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
show 4 more results
10.6% (n=650) vs 3.4% (n=325) placebo @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.6% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 5 Participants as posted
6.5% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 22 Participants as posted
8.2% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 5 Participants as posted
UC-related Hospitalization 6.6% (n=61) vs 8.3% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 4 Participants as posted
show 3 more results
5.2% (n=58) vs 8.3% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
5.6% (n=340) vs 8.3% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 19 Participants as posted
9.8% (n=61) vs 8.3% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 6 Participants as posted
HEMR 3.3% (n=61) vs 0% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 2 Participants as posted
show 3 more results
1.7% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 1 Participants as posted
2.9% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 10 Participants as posted
4.9% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 3 Participants as posted
UC-SQ -15.6 vs -7.4 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
-15.1 vs -7.4 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
-17.1 vs -7.4 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
-13.8 vs -7.4 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
IBDQ 40.3 vs 20.1 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 4 more results
42.6 vs 24.3 placebo score @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
40 vs 20.1 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
49.5 vs 20.1 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
37.4 vs 20.1 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
SF-36 PCS 6.35 vs 3.904 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
6.296 vs 3.904 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.719 vs 3.904 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
5.112 vs 3.904 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
SF-36 MCS 7.284 vs 3.094 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 3 more results
5.442 vs 3.094 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.777 vs 3.094 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
6.756 vs 3.094 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
FACIT-Fatigue 9 vs 3.7 placebo score @ 12wk1200 mg IV
absolute change · score
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
show 4 more results
7.9 vs 3.3 placebo score @ 12wk1200 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
8.3 vs 3.7 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
10.7 vs 3.7 placebo score @ 12wk1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
7.6 vs 3.7 placebo score @ 12wk600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3
UC-related Surgery 0% (n=61) vs 0% (n=60) placebo @ 12wk1200 mg IV
event count · % of participants
Induction
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 0 Participants as posted
show 3 more results
0% (n=58) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 0 Participants as posted
2.1% (n=340) vs 0% (n=60) placebo @ 12wk*1800 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 7 Participants as posted
1.6% (n=61) vs 0% (n=60) placebo @ 12wk*600 mg IV
NCT03398148 · Phase 2/3 · Ulcerative Colitis · phase 2/3 · converted to % from 1 Participants as posted

+ 8 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: risankizumab's landscape · SHR-1139's landscape